Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma - Wikidata - awgldk - TriplyDB

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

http://www.wikidata.org/entity/Q34534572

about

Barking up the right tree: advancing our understanding and treatment of lymphoma with a spontaneous canine model.The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Role of Bruton's tyrosine kinase in B cells and malignancies.Acalabrutinib: First Global Approval.Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma.

P2860

Q38371241-D64D96EE-84D4-4488-B1C7-FF2F96DF56F3 Q42368337-FBF3C1A8-4D06-4626-888D-5B7AC9CD9A58 Q47379071-11F09B5C-6CB6-47A0-AC5B-CE89507B3079 Q47424531-C136091A-BE1D-48AC-8FA1-4040EA8F44CE Q47898168-B9772BB8-0030-43C4-A123-1683B3F7E2CD Q49888075-9BFB6F49-7EEF-43C8-BDDF-F8023B2AC40C Q50055031-ED48EF50-7358-40A2-9317-CDF637C84430 Q55058455-3035ACAB-3702-4045-AAA8-FB48A9BC8F48

P2860

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

http://www.wikidata.org/entity/Q34534572

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@ast

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@en

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@nl

type

label

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@ast

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@en

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@nl

prefLabel

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@ast

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@en

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@nl

P1433

Q34534572-36548E10-D7C0-49D8-82B9-681503F78E17

P1476

Q34534572-3684A7DE-079B-448B-9CE8-D82A335EF061

P2093

Q34534572-243E6D7E-83FE-4F01-B147-42CC00735417

Q34534572-2F175BB6-6309-40AA-9791-A11EF564CCAB

Q34534572-484DD3F0-4183-43E1-A804-B006B00B743E

Q34534572-4E5E08B8-1D2F-4C47-8D8A-62C8BA988B20

Q34534572-55AA4868-C4D5-4ACC-95CD-A4DACEEF73AA

Q34534572-619D296D-9A7C-407F-A460-97C681737008

Q34534572-668460CF-9A41-4EA2-9BCD-06506D240E44

Q34534572-8D96BFB2-041C-4818-A35E-A3A1ACEBCCB7

Q34534572-9C39446C-FA25-47E3-BFCA-AA16D70C8672

Q34534572-AC14172F-58D3-4C10-8C87-E4E78A9DA4B5

P2860

Q34534572-0A4F4C0F-56D3-4BEC-B5FA-5E7A533AEA5F

Q34534572-0E6D0EF8-8483-420A-9A47-377B67F92C34

Q34534572-114595CA-4D8E-4008-BEC4-D3DE8613391E

Q34534572-2666A0CF-C72D-44E5-9607-4B4973060B93

Q34534572-2A4EDDFA-865B-4E8A-9D7F-6B2D101CB940

Q34534572-2F0D88ED-3B83-4FEB-9FBE-31E2F6A635EF

Q34534572-32D651FA-2799-4B46-93AD-66B136D14D12

Q34534572-3EA3775C-EC5F-400A-9333-EC28C8646986

Q34534572-40115E04-43B3-4213-AED9-723185CD6BCA

Q34534572-48D78E86-3B14-4384-95F6-73C2F2ECDA1A

P304

Q34534572-4A24B225-7CBE-4FF5-ABE3-769190E40886

P31

Q34534572-C844E291-37E0-4CF1-A767-5710BADFEDE7

P356

Q34534572-88427A70-A380-48E2-BB41-EAA0B12B84EB

P407

Q34534572-653EE509-6992-413F-AC9F-9813DEFE1FFC

P433

Q34534572-740ABCCC-C1F4-4FB7-B9F5-5E25F6AC6639

P478

Q34534572-8F95F657-DA40-4354-9C67-AC18512A94B9

P50

Q34534572-1AEEB7B5-88A8-4528-BDC4-569F91936497

Q34534572-645CFDBB-EA07-4F10-BA99-DA8116F155CD

P577

Q34534572-6BF02F21-6CE0-4B00-91B8-FBD9A0985B68

P698

Q34534572-FAB6A8B7-5E3B-4FC4-8E18-44261B57AD52

P932

Q34534572-A4D266E9-D9FB-48CD-8A23-E6EB2F167512

P356

JOURNAL.PONE.0159607

P1433

P1476

Preclinical Evaluation of the ...... of B-Cell Non-Hodgkin Lymphoma

@en

P2093

Ahmed Hamdy

http://www.w3.org/2001/XMLSchema#string

Allard Kaptein

http://www.w3.org/2001/XMLSchema#string

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Bart Van Lith

http://www.w3.org/2001/XMLSchema#string

Bridget K Urie

http://www.w3.org/2001/XMLSchema#string

Cecile Krejsa

http://www.w3.org/2001/XMLSchema#string

Cheryl A London

http://www.w3.org/2001/XMLSchema#string

Christopher C Coss

http://www.w3.org/2001/XMLSchema#string

Duncan S Russell

http://www.w3.org/2001/XMLSchema#string

Heather L Gardner

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

P304

e0159607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0159607

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Bonnie K Harrington

P577

2016-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27434128

http://www.w3.org/2001/XMLSchema#string

P932

4951150

http://www.w3.org/2001/XMLSchema#string